Investors participating in the Financing include New York-based ArcStone US Ventures and recognized CPG entrepreneur, John Celenza, co-founder of BioSteel
Toronto, Ontario–(Newsfile Corp. – October 24, 2023) – Harbour Solutions Importation Inc. (“Harbour” or the “Company“), the world’s leading coca leaf company, today announced the launch of an offering of its common shares under Rule 506(c) of Regulation D for gross proceeds of up to US$5,000,000 (the “Financing“).
The Financing will provide strategic capital to Harbour and enable accredited investors to participate in the growth of the rapidly emerging coca sector. In connection with the Financing, Harbour has secured investments from New York-based venture capital fund ArcStone US Ventures (“ArcStone“) (along with personal investments from ArcStone’s CEO Michael Astone and its Managing Director Jack Bensimon) as well as recognized CPG entrepreneur, John Celenza, co-founder and former CEO of BioSteel Sports Nutrition.
Earlier this year, Harbour became the first company to successfully import coca leaf extract into Canada, an effort that took many months to complete. Since then, the Company has successfully completed a secondary importation on an expedited basis.
“Harbour has diligently navigated through the complex regulatory processes to set a new standard for the expansion and growing influence in the coca leaf and derivative products sector,” said David Craig, Harbour’s CEO. “With the proceeds of the Financing, along with the strategic participation by ArcStone and John Celenza, Harbour will open up the power and the potential of coca leaf extract to the world through new and differentiated products.”
For thousands of years, coca has been heralded as a panacea among many cultures, offering benefits as a medicine, a tonic and a food. But for a variety of political reasons, its many medical and health benefits have gone unrecognized in Western culture. That is starting to change as the success of cannabis and psychedelics has generated renewed interest in once-stigmatized plant-based medicines.